000			03155nam a22002777a 4500
003			OSt
005			20240305192633.0
008			230113b |||||||| |||| 00| 0 eng d
020			_a9789535126669
020			_a9535126660
040			_cDLC
041			_aEnglish
082			_a615
100			_aOzcan Basaran _948026
222			_aCommon terms and phrases _bacenocoumarol acid anticoagulant effect anticoagulant reversal antithrombin apixaban assays assessment associated atrial fibrillation Beriplex Biochem bleeding models blood coagulation cell chiral Clin clinical clotting factors compared coumarinic cytochrome D-dimer dabigatran disease drug edoxaban efficacy embolism enantiomers enzymatic epoxide reductase factor IX factor VIIa factor Xa factor Xa inhibitors gene genetic hemorrhage hemostasis heparin heparin bridging human implantation increased infusion inhibition interaction intracranial IU/kg K-dependent coagulation factors major bleeding mechanism metabolism microsomal ml/min molecule NOACs NVAF oral anticoagulants p-GP patients pharmacokinetics phenprocoumon plasma polymorphism pregnancy procoagulant prophylaxis protein prothrombin complex concentrate recombinant factor VIIa renal reversal agent reversal of anticoagulation rivaroxaban rodenticides rodents surgery target Thromb Haemost Thromb Res thrombogenic thrombogenic risk factors thrombophilia thrombotic treatment trial venous thromboembolism venous thrombosis vitamin K vitamin K epoxide vitamin K-dependent coagulation vitamin Kantagonists vitro vivo VKOR activity VKORC1 mutations warfarin warfarin resistance
245			_aAnticoagulation Therapy
260			_aNew York: _bBoD – Books on Demand, _cc2016
300			_a150 pages
505			_aContents: Comparative Biology of the Resistance to Vitamin The Risk Factors of Thrombogenic Thrombophilia and Management of Anticoagulation Around Cardiac Implantable Prothrombin Complex Concentrate a General Antidote for Oral NonVitamin K Antagonist Oral Anticoagulants in Atrial NonVitamin K Antagonist Oral Anticoagulants Clinical Use
520			_aThe available parenteral and oral anticoagulants have a large clinical use. Understanding biochemistry of anticoagulants may help to improve therapeutic strategies. Resistance to vitamin K antagonist drugs might be a problem for rodent populations. Patients who have thrombogenic risk factors should be anticoagulated. The need for cardiac implantable electronic devices is increasing, and there is a substantial number of patients who are on oral anticoagulant therapy. Prothrombin complex concentrate and other plasma concentrates are useful to deal with over-coagulated situations. The efficacy and safety of non-vitamin K antagonist oral anticoagulants have been proven in large phase III trials. The real-world data suggest even better outcomes with these agents compared to vitamin K antagonists.
600			_xMedical / Nursing / Pharmacology _928586
600			_x Medical / Critical Care _927035
600			_xMedical  › Nursing  › Pharmacology _947517
700			_a Murat Biteker _948027
942			_2ddc _cEB
999			_c9718 _d9718